Status:
UNKNOWN
Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Uterine Cervical Cancer
Diffusion-weighted MRI
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Uterine cervical cancer is the second most common female malignancy. Therapy monitoring is essential to detect early recurrence. Diffusion-weighted magnetic resonance imaging is an emerging MRI imagin...
Eligibility Criteria
Inclusion
- Patients diagnosed with cervical uterine cancer are, on a voluntary basis, enrolled in the study. These are patients who either underwent curative chemoradiation (mainly patients with advanced stage cancer) or neoadjuvant chemotherapy (predominantly in patients with early stage cancer) before undergoing surgery.
Exclusion
- Patients with known contra-indications for MRI (cardiac pacemakers, cochlear implants, claustrophobic patients) will be excluded from this study. And so are patients with contra-indications to Gadolinium-based contrast agents and patients with a known restricted renal function (GFR \< 30 ml/min).
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01226264
Start Date
November 1 2010
End Date
April 1 2016
Last Update
December 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Gasthuisberg
Leuven, Leuven, Belgium, 3000